Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
V.ShelepovaE
505 After a three-year follow-up investigation, 54.1% and 56.3% of patients randomized to the ustekinumab q12w and q8w groups, respectively, achieved symptomatic relief at week 152 while on maintenance therapy
Less weight generally means less strain on your body, translating into Higher Energy Availability for daily tasks and exercise
Ethics declarations Competing interests M.M.V., S.C.L., L.A., R.K., S.S., Y.C., B.W., J.R.F., T.H., V.A.T., M.A., L.S., Y.Z., V.K., R.J., R.K.O., J.R.P., N.H
US$ 28.74
US$ 28.67
US$ 23.77
US$ 25.35
